Human medicines European public assessment report (EPAR): Exelon, rivastigmine, Date of authorisation: 11/05/1998, Revision: 51, Status: Authorised

Human medicines European public assessment report (EPAR): Erleada, apalutamide, Date of authorisation: 14/01/2019, Revision: 21, Status: Authorised

ICH E22 General considerations for patient preference studies - Scientific guideline

Human medicines European public assessment report (EPAR): Zoledronic Acid Accord, zoledronic acid, Date of authorisation: 16/01/2014, Revision: 14, Status: Authorised

Website outages and upgrades

Human medicines European public assessment report (EPAR): Apixaban Accord, apixaban, Date of authorisation: 23/07/2020, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Teriflunomide Accord, teriflunomide, Date of authorisation: 09/11/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Eribulin Baxter, eribulin, Date of authorisation: 27/06/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Acvybra, denosumab, Date of authorisation: 17/11/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Lenalidomide Accord, lenalidomide, Date of authorisation: 20/09/2018, Revision: 13, Status: Authorised